Novartis announced a phase 3b clinical trial to evaluate brolucizumab vs. aflibercept in the treatment of wet age-related macular degeneration.
The TALON trial is the first treat-to-control study and aims to demonstrate brolucizumab’s superiority in treatment interval duration, while maintaining noninferiority in visual acuity change, Joanne Chang, Novartis Ophthalmology’s worldwide medical affairs head, told Healio.com/OSN.
“We believe TALON will demonstrate that brolucizumab can enable an earlier treatment interval extension — up to 16 weeks — and that more
Uncategorized